Pliant Therapeutics, Inc.(PLRX)

Description: Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins that it is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both IPF and PSC. Pliant is currently recruiting two Phase 2a trials of PLN-74809 for the treatment of IPF and plans to initiate a Phase 2a trial in PSC in the second half of 2020. Pliant's second product candidate, PLN-1474, is a small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis, or NASH, which Pliant has partnered with Novartis. PLN-1474 is currently undergoing a Phase 1 trial. In addition to clinical stage programs, Pliant currently has two preclinical programs targeting oncology and muscular dystrophies.

---

Keywords: Medicine Alcohol Hepatitis Fibrosis Idiopathic Pulmonary Fibrosis Steatohepatitis Non Alcoholic Fatty Liver Disease Orphan Drug Pulmonary Fibrosis Hepatology Drug Design Liver Fibrosis Treatment Of Idiopathic Pulmonary Fibrosis Treatment Of Fibrosis Muscular Dystrophies Primary Sclerosing Cholangitis Integrin

---

Home Page: pliantrx.com

PLRX Technical Analysis

260 Littlefield Avenue
South San Francisco, CA 94080
United States
Phone: 650 481 6770

---

Officers

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)